Amir Moheet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amir Moheet has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Lynn E. Eberly
Center for Magnetic Resonance Research, Department of Radiology University of Minnesota Minneapolis Minnesota USA
16 shared publications Anjali Kumar
Department of Medicine University of Minnesota Minneapolis Minnesota USA
10 shared publications- Gülin Öz
Center for Magnetic Resonance Research, Department of Radiology University of Minnesota Minneapolis Minnesota USA
10 shared publications - Elizabeth R. Seaquist
Department of Medicine, University of Minnesota, Minneapolis, MN
8 shared publications - Silvia Mangia
Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA
8 shared publications Antoinette Moran
Division of Pediatric Endocrinology, Department of Pediatrics, University of Minnesota, Minneapolis, United States
7 shared publications
Latest Publications
- 20 April 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (8) , 1227-1232
Agreement Between HbA1C and Continuous Glucose Monitoring–Derived Glycemic Metrics in Adults With Cystic Fibrosis Related Diabetes
- 20 April 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (8) , 1227-1232
Agreement Between HbA1C and Continuous Glucose Monitoring–Derived Glycemic Metrics in Adults With Cystic Fibrosis Related Diabetes
- Open Access
- 19 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (8)
Disrupted neurovascular-endocrine coupling in type 1 diabetes with impaired awareness of hypoglycemia
BACKGROUND: Recurrent hypoglycemia in type 1 diabetes (T1D) may culminate in impaired awareness of hypoglycemia (IAH). While neuroimaging studies identified affected brain regions, more complex perspectives integrating vascular dynamics with endocrine profile are needed. METHODS: Here, 26 healthy adults, 30 T1D patients with normal hypoglycemia awareness (NAH), and 25 T1D patients with IAH underwent a hyperinsulinemic stepped clamp (euglycemia → hypoglycemia 50 mg/dL) combined with pseudo-continuous arterial spin-labeling MRI. Cerebral blood flow (CBF) and sympathetic vasomotor range (0.02–0.05 Hz) CBF oscillations were modeled against serially sampled plasma cortisol, epinephrine, norepinephrine, and glucagon. RESULTS: In healthy individuals treated as controls, hypoglycemia evoked robust thalamo-striatal and salience–interoceptive CBF increases (mean Cohen’s d across significant clusters = 0.93) and suppression of vasomotor oscillations ( d = 0.71). T1D retained CBF response but failed to attenuate oscillations ( d T1D>controls = 0.43). IAH further blunted hypoglycemia-associated CBF increase, especially in thalamus, striatum, and insula ( d NAH>IAH = 0.51). Hormone-CBF coupling differed quantitatively: cortisol/epinephrine–CBF correlations were positive in controls ( r = 0.37/0.26), negative in NAH (–0.16/–0.40), and strongly positive in IAH (0.42/0.46). CONCLUSION: Thus, our findings indicate that T1D disrupts dynamic, sympathetic modulation of CBF, whereas IAH additionally impairs perfusion reserve and shows maladaptive catecholamine-dependent CBF regulation, suggesting a qualitatively distinct neurovascular phenotype. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02747680 and NCT02866435. FUNDING: NIH (P41-EB-015894, P30-NS-076408, R01-DK-099137, R56-DK-099137, and DP1 AG093028); National Center for Advancing Translational Sciences of the NIH (KL2-TR-000113 and UL1-TR-000114); DP1 AG093028; Charles University, Czech Republic (Cooperatio Program, research area NEUR), Brain Dynamics (grant number CZ.02.01.01/00/22_008/0004643); General University Hospital in Prague (MH CZ-DRO-VFN64165).
- 19 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (8)
Open AccessDisrupted neurovascular-endocrine coupling in type 1 diabetes with impaired awareness of hypoglycemia
BACKGROUND: Recurrent hypoglycemia in type 1 diabetes (T1D) may culminate in impaired awareness of hypoglycemia (IAH). While neuroimaging studies identified affected brain regions, more complex perspectives integrating vascular dynamics with endocrine profile are needed. METHODS: Here, 26 healthy adults, 30 T1D patients with normal hypoglycemia awareness (NAH), and 25 T1D patients with IAH underwent a hyperinsulinemic stepped clamp (euglycemia → hypoglycemia 50 mg/dL) combined with pseudo-continuous arterial spin-labeling MRI. Cerebral blood flow (CBF) and sympathetic vasomotor range (0.02–0.05 Hz) CBF oscillations were modeled against serially sampled plasma cortisol, epinephrine, norepinephrine, and glucagon. RESULTS: In healthy individuals treated as controls, hypoglycemia evoked robust thalamo-striatal and salience–interoceptive CBF increases (mean Cohen’s d across significant clusters = 0.93) and suppression of vasomotor oscillations ( d = 0.71). T1D retained CBF response but failed to attenuate oscillations ( d T1D>controls = 0.43). IAH further blunted hypoglycemia-associated CBF increase, especially in thalamus, striatum, and insula ( d NAH>IAH = 0.51). Hormone-CBF coupling differed quantitatively: cortisol/epinephrine–CBF correlations were positive in controls ( r = 0.37/0.26), negative in NAH (–0.16/–0.40), and strongly positive in IAH (0.42/0.46). CONCLUSION: Thus, our findings indicate that T1D disrupts dynamic, sympathetic modulation of CBF, whereas IAH additionally impairs perfusion reserve and shows maladaptive catecholamine-dependent CBF regulation, suggesting a qualitatively distinct neurovascular phenotype. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02747680 and NCT02866435. FUNDING: NIH (P41-EB-015894, P30-NS-076408, R01-DK-099137, R56-DK-099137, and DP1 AG093028); National Center for Advancing Translational Sciences of the NIH (KL2-TR-000113 and UL1-TR-000114); DP1 AG093028; Charles University, Czech Republic (Cooperatio Program, research area NEUR), Brain Dynamics (grant number CZ.02.01.01/00/22_008/0004643); General University Hospital in Prague (MH CZ-DRO-VFN64165).
- Open Access
- 27 July 2025
- Published by Wiley in NMR in Biomedicine
- Vol. 38 (9) , e70108
Neurochemical Profiles of Prefrontal Cortex and Hypothalamus at 3 and 7 T During Controlled Euglycemia: Evaluation in a Cohort With Type 1 Diabetes
With the increasing adoption of ultrahigh‐field MRI scanners, there is a growing interest in migrating MRS studies from 3 to 7 T. Prior field comparisons of MRS in healthy volunteers demonstrated better reliability of quantification at 7 T, particularly for weakly represented metabolites. Neurochemical quantification has not been compared at 3 T versus 7 T in clinical cohorts and under controlled physiological conditions. In this exploratory study, we analyzed MRS data from the hypothalamus and prefrontal cortex volumes of interest (VOIs) that were collected from the same individuals with Type 1 diabetes at 3 and 7 T as a part of a larger study investigating cerebral responses to glycemic changes. Seventeen individuals underwent MRS during euglycemic clamps at both 3 T and 7 T, allowing us to compare metabolite concentrations obtained at the two fields with a consensus‐recommended short‐echo semi‐LASER protocol under the same physiological conditions. Our aim was to examine whether there are systematic biases in neurochemical concentrations measured at 3 T versus 7 T and to assess whether creatine (tCr) ratios would reduce or eliminate such biases. High‐quality spectra were obtained from both VOIs and fields, with 8–15 reliably quantified (mean Cramér–Rao lower bounds ≤ 20%) metabolites from LCModel. Whereas neurochemical profiles were highly similar between 3 and 7 T, several metabolites exhibited systematic differences with water‐referenced quantifications, such as glucose + taurine (Glc + Tau) and phosphoethanolamine. Quantifications with tCr as reference did not alleviate the biases and, in fact, resulted in a larger number of significant differences due to systematic biases in the tCr concentration. Pearson correlation analysis showed significant associations for several metabolites between 3 and 7 T, suggesting that interindividual differences in neurochemical levels are detectable. Associations were stronger when using tCr ratios. Importantly, hypothalamic Glc + Tau showed a strong correlation between fields at these tightly regulated euglycemic conditions, opening the possibility to detect individualized glucose concentrations in this brain region that participates in the regulation of blood glucose levels.
- 27 July 2025
- Published by Wiley in NMR in Biomedicine
- Vol. 38 (9) , e70108
Open AccessNeurochemical Profiles of Prefrontal Cortex and Hypothalamus at 3 and 7 T During Controlled Euglycemia: Evaluation in a Cohort With Type 1 Diabetes
With the increasing adoption of ultrahigh‐field MRI scanners, there is a growing interest in migrating MRS studies from 3 to 7 T. Prior field comparisons of MRS in healthy volunteers demonstrated better reliability of quantification at 7 T, particularly for weakly represented metabolites. Neurochemical quantification has not been compared at 3 T versus 7 T in clinical cohorts and under controlled physiological conditions. In this exploratory study, we analyzed MRS data from the hypothalamus and prefrontal cortex volumes of interest (VOIs) that were collected from the same individuals with Type 1 diabetes at 3 and 7 T as a part of a larger study investigating cerebral responses to glycemic changes. Seventeen individuals underwent MRS during euglycemic clamps at both 3 T and 7 T, allowing us to compare metabolite concentrations obtained at the two fields with a consensus‐recommended short‐echo semi‐LASER protocol under the same physiological conditions. Our aim was to examine whether there are systematic biases in neurochemical concentrations measured at 3 T versus 7 T and to assess whether creatine (tCr) ratios would reduce or eliminate such biases. High‐quality spectra were obtained from both VOIs and fields, with 8–15 reliably quantified (mean Cramér–Rao lower bounds ≤ 20%) metabolites from LCModel. Whereas neurochemical profiles were highly similar between 3 and 7 T, several metabolites exhibited systematic differences with water‐referenced quantifications, such as glucose + taurine (Glc + Tau) and phosphoethanolamine. Quantifications with tCr as reference did not alleviate the biases and, in fact, resulted in a larger number of significant differences due to systematic biases in the tCr concentration. Pearson correlation analysis showed significant associations for several metabolites between 3 and 7 T, suggesting that interindividual differences in neurochemical levels are detectable. Associations were stronger when using tCr ratios. Importantly, hypothalamic Glc + Tau showed a strong correlation between fields at these tightly regulated euglycemic conditions, opening the possibility to detect individualized glucose concentrations in this brain region that participates in the regulation of blood glucose levels.
- Open Access
- 16 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Comparative effectiveness of combining antidiabetic medications to treat renal impairment in patients with type 2 diabetes mellitus
The comparative renoprotective effects of metformin-GLP-1 RA (glucagon-like peptide 1 receptor agonist), metformin-DPP-4i (dipeptidyl peptidase 4 inhibitor) and metformin-oADM (other antidiabetes medication) in patients with DKD (diabetic kidney disease) were evaluated by assessing the associations between renal impairment and combination therapies. Patients initially diagnosed with DKD between January 1, 2010, and January 1, 2017, were included. Those receiving combination treatment with metformin-GLP-1 RA, metformin-DPP-4i, or metformin-oADM were selected and paired. A logistic regression model was applied to generate odds ratios with 95% confidence intervals to assess the associations between the composite renal impairment outcomes and the combination ADM (antidiabetes medication) groups. Sensitivity analyses were also performed. Renal impairment was significantly reduced in patients who were treated with metformin-GLP-1 RA than in those treated with metformin-DPP-4i in the primary and secondary analyses (OR 0.60, P < 0.05 for the primary outcome; OR 0.44, P < 0.05 for the secondary outcome). The associations of renal impairment risk and ADM combination therapies with metformin-DPP-4i versus metformin-oADM were not statistically significant in either the primary or secondary analysis (OR = 1.22, P = 0.20 for the primary outcome; OR = 0.90, P = 0.53 for the secondary outcome). The results of the sensitivity analyses were consistent with those of the main analysis. The combination metformin-GLP-1 RA was associated with fewer renal impairment events compared to metformin-DPP-4i and metformin-oADM, indicating potential additive or synergistic effects within the combination metformin-GLP-1 RA group. Metformin-DPP-4i did not significantly improve renal impairment outcomes in this study.
- 16 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessComparative effectiveness of combining antidiabetic medications to treat renal impairment in patients with type 2 diabetes mellitus
The comparative renoprotective effects of metformin-GLP-1 RA (glucagon-like peptide 1 receptor agonist), metformin-DPP-4i (dipeptidyl peptidase 4 inhibitor) and metformin-oADM (other antidiabetes medication) in patients with DKD (diabetic kidney disease) were evaluated by assessing the associations between renal impairment and combination therapies. Patients initially diagnosed with DKD between January 1, 2010, and January 1, 2017, were included. Those receiving combination treatment with metformin-GLP-1 RA, metformin-DPP-4i, or metformin-oADM were selected and paired. A logistic regression model was applied to generate odds ratios with 95% confidence intervals to assess the associations between the composite renal impairment outcomes and the combination ADM (antidiabetes medication) groups. Sensitivity analyses were also performed. Renal impairment was significantly reduced in patients who were treated with metformin-GLP-1 RA than in those treated with metformin-DPP-4i in the primary and secondary analyses (OR 0.60, P < 0.05 for the primary outcome; OR 0.44, P < 0.05 for the secondary outcome). The associations of renal impairment risk and ADM combination therapies with metformin-DPP-4i versus metformin-oADM were not statistically significant in either the primary or secondary analysis (OR = 1.22, P = 0.20 for the primary outcome; OR = 0.90, P = 0.53 for the secondary outcome). The results of the sensitivity analyses were consistent with those of the main analysis. The combination metformin-GLP-1 RA was associated with fewer renal impairment events compared to metformin-DPP-4i and metformin-oADM, indicating potential additive or synergistic effects within the combination metformin-GLP-1 RA group. Metformin-DPP-4i did not significantly improve renal impairment outcomes in this study.
- Open Access
- 8 July 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 143 (2) , 424-443
Diabetes Mellitus in Pregnancy: Implications for Obstetric Anesthesia
Diabetes in pregnancy is a common obstetric comorbidity that increases the risks of pregnancy-specific complications. The authors describe in this review how understanding ambulatory use of insulin can impact peripartum anesthesia care. Additionally, they describe the appropriate delivery, dosing, and timing of insulin during birth as relevant for anesthesiologists. They discuss the indications and limitations of technologies such as continuous glucose monitors and insulin pumps in pregnancy, and describe their relevance and appropriate management in the perioperative and peripartum period. Finally, the authors review the unique complication of euglycemic diabetic ketoacidosis and provide appropriate management strategies, as anesthesiologists may be in a position to recognize this complication that could otherwise be overlooked.
- 8 July 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 143 (2) , 424-443
Open AccessDiabetes Mellitus in Pregnancy: Implications for Obstetric Anesthesia
Diabetes in pregnancy is a common obstetric comorbidity that increases the risks of pregnancy-specific complications. The authors describe in this review how understanding ambulatory use of insulin can impact peripartum anesthesia care. Additionally, they describe the appropriate delivery, dosing, and timing of insulin during birth as relevant for anesthesiologists. They discuss the indications and limitations of technologies such as continuous glucose monitors and insulin pumps in pregnancy, and describe their relevance and appropriate management in the perioperative and peripartum period. Finally, the authors review the unique complication of euglycemic diabetic ketoacidosis and provide appropriate management strategies, as anesthesiologists may be in a position to recognize this complication that could otherwise be overlooked.
- 14 March 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (4) , 755-758
Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor
- 14 March 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (4) , 755-758
Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor
- 17 March 2023
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (6) , 1805-1811
The impact of elexacaftor/tezacaftor/ivacaftor on body composition in a small cohort of youth with cystic fibrosis
Background: The effects of elexacaftor‐tezacaftor‐ivacaftor (ETI) on body composition in people with CF (pwCF) are unknown.Methods: Dual‐energy X‐ray absorptiometry fat‐free mass and fat mass adjusted for height (FMI) as well as oral glucose tolerance test derived measures of insulin secretion and sensitivity were compared before and after ETI initiation in eight pwCF.Results: Patients median age: 22 years interquartile range (IQR: 16–28), 87.5% male, median time on ETI:11 months. Weight z‐score increased from −0.52 to 0.18 (p = 0.014); FMI increased from 4.12 to 6.29 (p = 0.014). Insulin secretion (C pep iAUC/Gluc iAUC) increased from 8.71 to 14.21 (p = 0.021), insulin resistance (HOMA2 IR) increased from 0.73 to 1.25 (p = 0.014) and insulin sensitivity decreased (Matsuda) 8.88 to 5.58 (p = 0.036).Conclusions: ETI resulted in increased weight and fat mass. BMI and muscle mass did not change. Both insulin secretion and insulin resistance increased. Longer‐term metabolic consequences of ETI need further investigation.
- 17 March 2023
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (6) , 1805-1811
The impact of elexacaftor/tezacaftor/ivacaftor on body composition in a small cohort of youth with cystic fibrosis
Background: The effects of elexacaftor‐tezacaftor‐ivacaftor (ETI) on body composition in people with CF (pwCF) are unknown.Methods: Dual‐energy X‐ray absorptiometry fat‐free mass and fat mass adjusted for height (FMI) as well as oral glucose tolerance test derived measures of insulin secretion and sensitivity were compared before and after ETI initiation in eight pwCF.Results: Patients median age: 22 years interquartile range (IQR: 16–28), 87.5% male, median time on ETI:11 months. Weight z‐score increased from −0.52 to 0.18 (p = 0.014); FMI increased from 4.12 to 6.29 (p = 0.014). Insulin secretion (C pep iAUC/Gluc iAUC) increased from 8.71 to 14.21 (p = 0.021), insulin resistance (HOMA2 IR) increased from 0.73 to 1.25 (p = 0.014) and insulin sensitivity decreased (Matsuda) 8.88 to 5.58 (p = 0.036).Conclusions: ETI resulted in increased weight and fat mass. BMI and muscle mass did not change. Both insulin secretion and insulin resistance increased. Longer‐term metabolic consequences of ETI need further investigation.
- 2 December 2022
- Published by Elsevier in Endocrine Practice
- Vol. 29 (4) , 286-294
Clinical Presentation and Diagnostic Approach to Hypoglycemia in Adults Without Diabetes Mellitus
- 2 December 2022
- Published by Elsevier in Endocrine Practice
- Vol. 29 (4) , 286-294
Clinical Presentation and Diagnostic Approach to Hypoglycemia in Adults Without Diabetes Mellitus
- Open Access
- 1 August 2022
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 6 (9) , bvac107
Relationship Between Hypoglycemia Awareness Status on Clarke/Gold Methods and Counterregulatory Response to Hypoglycemia
Context: Impaired awareness of hypoglycemia (IAH) is characterized by the diminished ability to perceive symptoms of hypoglycemia. Gold and Clark questionnaires are commonly used to identify patients with IAH. The relationship between IAH status on questionnaires and a person’s symptom and epinephrine responses to hypoglycemia are not well understood. Objective: We aimed to examine the relationship between hypoglycemia awareness status on Clarke and Gold questionnaires with both hormonal and symptomatic responses to experimental hypoglycemia. Methods: In this university medical center study, we examined data from 78 subjects with type 1 diabetes (T1D) who completed both questionnaires and underwent a hyperinsulinemic hypoglycemic clamp (target glucose 50 mg/dL). Results: Clarke and Gold scores were highly correlated with one another (r = 0.82) and each had a moderate negative relationship with epinephrine (Clarke: r = -0.51, Gold: r = -0.50) and total symptom response (Clarke: r = −0.59, Gold: r = −0.57). However, 32% of the subjects were classified inconsistently by Clark vs Gold. A clustering analysis was done to examine how disagreement between the 2 questionnaires on IAH classification relates to epinephrine and symptoms responses during hypoglycemia. Subjects who had partial loss of symptoms or of epinephrine response were more likely to be classified inconsistently. Conclusion: Our results show that IAH classification may be discordant between Clark and Gold questionnaires and that hypoglycemia awareness status on Clarke and Gold questionnaires poorly predicts hormonal and symptomatic responses to hypoglycemia in subjects with T1D and moderate blunting of symptoms or epinephrine.
- 1 August 2022
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 6 (9) , bvac107
Open AccessRelationship Between Hypoglycemia Awareness Status on Clarke/Gold Methods and Counterregulatory Response to Hypoglycemia
Context: Impaired awareness of hypoglycemia (IAH) is characterized by the diminished ability to perceive symptoms of hypoglycemia. Gold and Clark questionnaires are commonly used to identify patients with IAH. The relationship between IAH status on questionnaires and a person’s symptom and epinephrine responses to hypoglycemia are not well understood. Objective: We aimed to examine the relationship between hypoglycemia awareness status on Clarke and Gold questionnaires with both hormonal and symptomatic responses to experimental hypoglycemia. Methods: In this university medical center study, we examined data from 78 subjects with type 1 diabetes (T1D) who completed both questionnaires and underwent a hyperinsulinemic hypoglycemic clamp (target glucose 50 mg/dL). Results: Clarke and Gold scores were highly correlated with one another (r = 0.82) and each had a moderate negative relationship with epinephrine (Clarke: r = -0.51, Gold: r = -0.50) and total symptom response (Clarke: r = −0.59, Gold: r = −0.57). However, 32% of the subjects were classified inconsistently by Clark vs Gold. A clustering analysis was done to examine how disagreement between the 2 questionnaires on IAH classification relates to epinephrine and symptoms responses during hypoglycemia. Subjects who had partial loss of symptoms or of epinephrine response were more likely to be classified inconsistently. Conclusion: Our results show that IAH classification may be discordant between Clark and Gold questionnaires and that hypoglycemia awareness status on Clarke and Gold questionnaires poorly predicts hormonal and symptomatic responses to hypoglycemia in subjects with T1D and moderate blunting of symptoms or epinephrine.